Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Executive Summary
Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.
You may also be interested in...
US FDA's New Drug Assessors More Experienced With Rare Disease Issues
Now most, if not all, assessment divisions within the Office of New Drugs have dealt with issues surrounding small trials and rare diseases, defying common belief that experience was spread unequally.
US FDA Should Offer Formal Declaration Of Orphan Drug Flexibility, Attorney Says
Attorney Frank Sasinowski says the agency should include new "boilerplate language" in official documents describing scientific flexibility for orphan drug approval requirements.
US FDA Searches For Consistency On Assessment Of Real-World Evidence
As more sponsors begin using RWE, the agency is establishing procedures and training to ensure assessors consistently apply policies.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: